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Abstract 30 
Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma able to transform 31 
into germinal center-type diffuse large B-cell lymphoma (DLBCL). We describe four 32 
extraordinary cases of FL, which progressed to TdT+CD20- precursor B-lymphoblastic 33 
lymphoma (B-LBL). FISH analysis showed that all four B-LBLs had acquired a MYC 34 
translocation upon transformation. Comparative genomic hybridization analysis of one 35 
case demonstrated that in addition to 26 numerical aberrations that were shared between 36 
the FL and B-LBL, deletion of CDKN2A/B and 17q11, 14q32 amplification and copy-37 
neutral LOH of 9p were gained in the B-LBL cells. Whole-exome sequencing revealed 38 
mutations in FMN2, NEB and SYNE1 and a nonsense mutation in KMT2D, all shared by 39 
the FL and B-LBL and TNFRSF14, SMARCA2, CCND3mutations uniquely present in the 40 
B-LBL. Remarkably, all four FL – B-LBL pairs expressed IgG. In two B-LBLs, evidence 41 
was obtained for ongoing rearrangement of immunoglobulin (IG) light variable genes and 42 
expression of the surrogate light chain. IGHV mutation analysis showed that all FL – B-43 
LBL pairs harbored identical or near-identical somatic mutations. Based on the somatic 44 
gene alterations found in the IG and non-IG genes, we conclude that the FLs and B-LBLs 45 
did not develop in parallel from early t(14;18)-positive IG unmutated precursors, but that 46 
the B-LBLs developed from preexistent FL subclones that accumulated additional genetic 47 
damage.  48 
49 
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Introduction 50 
 51 
Follicular lymphomas (FLs) are the prototypic germinal center (GC)-derived B-cell non-52 
Hodgkin’s lymphomas 1 and cytologically and histologically resemble normal GCs. In 53 
accordance, FLs share a gene expression profile with normal centroblasts and centrocytes 54 
2 and express somatically hypermutated B-cell antigen receptors (BCR), which in ~25% 55 
of cases are of the non-IgM isotype.3, 4  56 
FLs have an indolent clinical behavior with a reported median survival of 8 to 10 57 
years after diagnosis.1 However, 20-60% of FLs transform into higher-grade 58 
malignancies, an event associated with an aggressive clinical course, poor therapy 59 
responses and short survival.5 Usually, FLs transform into other GC-type lymphomas, 60 
most often diffuse large B-cell lymphomas (DLBCL) or, less commonly, Burkitt-like 61 
lymphomas (referred to in the latest WHO classification as B-cell lymphoma 62 
unclassifiable with features intermediate between DLBCL and Burkitt-lymphoma).5, 6 63 
Infrequently, these prototypic GC-like malignancies transform into precursor B-64 
lymphoblastic lymphomas (B-LBL).7-15 Studies on sporadic cases described so far 65 
revealed that such B-LBLs carried BCL2 translocations, indicative for a clonal 66 
relationship with the preceding FLs. Karyotype analyses showed a variety of 67 
chromosomal alterations gained in the B-LBLs, among which MYC locus translocations 68 
were most frequently observed (in 18/19 (95%) of the described cases).7-15 Lymphomas 69 
with two recurrent translocations, one of which being MYC, are referred to as “double-70 
hit-B-cell lymphomas” and have a dismal prognosis.6  71 
Here we analyzed four FLs that transformed into B-LBLs. We demonstrate that 72 
these B-LBLs phenotypically and functionally display key features of early B cells and 73 
that, in addition to MYC translocations, also BCL6 gene translocation may accompany 74 
this infrequent mode of FL progression. Genome-wide copy number variation analysis 75 
and whole-exome sequencing (WES) of one of the transformed FLs demonstrated that a 76 
limited number of genomic alterations was gained in the B-LBLs, including deletions of 77 
the tumor suppressor genes CDKN2A/B and NF-1 and mutations in TNFRSF14, 78 
SMARCA2 and CCND3. 79 
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Materials and methods 80 
 81 
Patient material.  82 
The clinicopathological characteristics of the four patients with a FL that transformed 83 
into a B-LBL are shown in Table 1. This study was conducted in accordance with the 84 
ethical standards in our institutional medical committee on human experimentation, as 85 
well as in agreement with the Helsinki Declaration of 1975, revised in 1983. 86 
 87 
Clinico-pathological history of the four patients. 88 
TF 1: A FL grade I was diagnosed, which was treated with chlorambucil. After one year a 89 
B-LBL was diagnosed and the patient was treated with high dose chemotherapy 90 
consisting of iphosphamide, etoposide, methotrexate and two consolidation cycles with 91 
cytarabine, etoposide and methotrexate. Complete remission was reached. A few weeks 92 
later progression of the disease occurred and no further treatment was undertaken. The 93 
patient died subsequently. TF 2: A FL grade I was diagnosed, which was not treated. Two 94 
years later a B-LBL was diagnosed, which was treated with daunorubicin, vincristine, 95 
prednisone, asparaginase and methotrexate. Three months later the B-LBL reoccurred. 96 
The patient was treated with dexamethasone, but died a few weeks later. TF 3: A FL 97 
grade I was diagnosed. Two years later, laboratory evaluation showed a leukocyte count 98 
of 10.7 x 109/L with 38% atypical lymphocytes. Immunophenotyping demonstrated two 99 
lymphocytic populations, i.e. one population of mature monoclonal B cells and a distinct 100 
population of lymphoid blasts. Combined chemotherapy with cytarabin, etoposide and 101 
methotrexate was started. Complete remission was established following two additional 102 
courses of vincristine, dexamethason and adriamycine. Consolidation therapy consisted 103 
of cytarabin and asparaginase. Shortly thereafter the disease relapsed. Local radiotherapy 104 
was given. The patient died a few weeks later. TF 4: A FL was diagnosed, which was 105 
treated with 8 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine and 106 
prednisolone (R-CHOP). A year later, PET-CT scan showed lesions in the abdominal 107 
wall and in the retroperitoneum, which pathologically turned out to be a DLBCL and a B-108 
LBL, respectively. Rituximab combined with dexamethasone, high dose cytarabine and 109 
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cisplatin (R-DHAP) treatment was started but eventually the patient died several months 110 
later. 111 
 112 
Immunohistochemistry.  113 
Immunohistochemical stainings were performed on acetone-fixed cryostat sections and 114 
formalin-fixed paraffin-embedded (FFPE) tissue using Powervision+ detection system 115 
(Immunovision technologies, Daly City, CA). Monoclonal antibodies used: CD20 (B-116 
Ly1), CD21-L (DRC-1), BCL2 (124), BCL6 (PG-B6P), CD79a (HM57), CD19 (HD37), 117 
Igλ (A193), Igκ (A191) (Dako, Glostrup, Denmark), CD10 (CALLA) and PAX5 (24) 118 
(Becton and Dickinson (BD), Erembodegem-Aalst, Belgium) and CD3 (SP7; Labvision, 119 
Neomarkers, Fremont, CA) were used. Terminal deoxynucleotidyl transferase (TdT) was 120 
stained with a polyclonal serum (Klinipath, Duiven, The Netherlands).  121 
 122 
RNA isolation, cDNA synthesis 123 
RNA was isolated using TRIZOL reagent (Invitrogen, Breda, the Netherlands) and 124 
complementary DNA (cDNA) was synthesized.3 Immunoglobulin heavy chain variable 125 
region (IGHV) transcripts were amplified by PCR.16, 17 In some experiments, IGHV-PCR 126 
products were cloned in pTOPO-TA-vectors and sequenced. IGHV genes were identified 127 
using V-Quest (http://www.imgt.org/IMGT_vquest/vquest?livret=0&Option=humanIg).18 128 
VpreB and Lambda5 were amplified with the respective primer pairs: 5’-129 
CTCATGCACTTTGTCTACTG-3’ / 5’-CTGGCTCTTGTCTGATTGTGAG-3’ and 5’-130 
CTCCTGTCCTGCTCATGCTG-3’ / 5’-GTACACACCGATGTCATGGTCG-3’.The 131 
BCL2 PCR was performed on DNA, as described.19 132 
 133 
Fluorescence in situ hybridization.  134 
Chromosomal aberrations were investigated in 4 µm thick FFPE tissue sections by 135 
fluorescence in situ hybridization (FISH). A segregation-detection assay was used to 136 
detect breaks in BCL2 (probe Y5407), BCL6 (probe Y5408) and MYC (probe Y5410) 137 
(Dako).  138 
 139 
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Cell sorting 140 
Lymph node suspensions of TF3b were stained with CD19-APC, CD10-PerCP-Cy5.5 141 
and CD20-FITC monoclonal antibodies (BD). Cells were sorted in small 142 
CD19+CD10+CD20lo cells, small CD19+CD10+CD20hi cells, small CD19+CD10–CD20hi 143 
cells and large CD19+CD10+CD20lo cells by using a FACSAria (BD).  144 
 145 
Comparative genomic hybridization-array 146 
Genomic DNA was isolated using Qiagen’s DNeasy kit and analyzed for copy number 147 
variation (CNV) using HumanCytoSNP-12 BeadChips (Illumina, San Diego, CA). 148 
Processing of DNA samples, hybridization, staining and scanning of the BeadChips were 149 
performed according to the Illumina Infinium II protocol at the array facility of 150 
ServiceXS (Leiden, the Netherlands). Data was analyzed using Illumina GenomeStudio 151 
software (version 2009.2). The LogR ratio (LRR) and the B allele frequency (BAF) data 152 
were processed into the OverUnder plugin as described previously20 and copy numbers 153 
were calculated. Due to lack of normal tissue, it cannot be excluded that some of the 154 
CNVs are germline polymorphisms.  155 
 156 
Whole-exome sequencing 157 
Genomic DNA was amplified using the illustra GenomiPhi V2 DNA amplification kit 158 
(GE Healthcare, Little Chalfont, UK). Unamplified DNA of the B-LBL isolated from 159 
blood was used to control for amplification errors. Fragmentation was performed with the 160 
Covaris sonicator (GC Biotec, Alphen aan de Rijn, The Netherlands). Library preparation 161 
was performed using Solid chemistry. An exome capture was performed with Whole-162 
exome capture EZ version 3 of Nimblegen (Roche, Almere, The Netherlands) with 163 
platform-specific adaptors and blockers. Clonal amplification of the captured library was 164 
performed by emulsion PCR (Life Technologies). Finally, samples were sequenced on a 165 
Solid 5500 xl sequencer. Obtained data was processed according to the NGS pipeline 166 
described by Houten et al.21 Due to lack of normal tissue, only differential variants 167 
between FL and B-LBL could be determined. In addition, in our WES data we also 168 
checked for mutations in sets of 92 and 40 genes, previously found to be mutated in WES 169 
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data of FLs and B-cell acute lymphoblastic leukemias (B-ALLs), respectively 170 
(Supplementary Table 1).5, 22-26 Eleven mutations, in 10 genes identified in TF3b, were 171 
validated by Sanger sequencing in TF3b and in addition, these 11 mutations were 172 
examined in TF1a, TF2a and TF2c. Moreover, EZH2, which is frequently mutated in FL, 173 
was screened for mutations in TF1a and TF3b.174 
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Results 175 
 176 
Histology and phenotype of four FLs before and after transformation into B-LBLs. 177 
Before transformation, the four FLs (TF1a-4a) displayed a follicular growth pattern with 178 
a characteristic phenotype, i.e. CD20+, CD79a+, BCL2+ cells co-expressing the GC 179 
markers CD10 and BCL6 that expanded in networks of follicular dendritic cells (Tables 1 180 
and 2). After B-LBL transformation, the follicular architecture of TF1, 2 and 4 was lost. 181 
The tumor cells of all four cases still expressed CD79a, CD10 and BCL2, but were 182 
devoid of CD20. In addition, all B-LBLs expressed terminal deoxynucleotidyl transferase 183 
(TdT). In the TF2b B-LBL approximately 10% of the tumor cells stained positive for 184 
TdT. However, no TdT expression was observed in the TF2c biopsy. In TF3b, the 185 
follicular growth pattern was in part retained and alternated with sheets of lymphoblastic 186 
cells (Figure 1). To analyze the molecular features of the entities in TF3b, CD19+ cells of 187 
lymph node suspensions were sorted by FACS based on size and expression of CD20 and 188 
CD10, in: (I) small CD19+CD10+CD20lo cells, (II) small CD19+CD10+CD20hi cells, (III) 189 
small CD19+CD10–CD20hi cells and (IV) large CD19+CD10+CD20lo cells. Both CD20lo 190 
fractions expressed TdT, as determined by RT-PCR, demonstrating that these fractions 191 
represent the B-LBL (Supplementary Figure S1). Of note, the FL of TF4 transformed into 192 
a DLBCL before transforming into B-LBL (Table 1). 193 
 194 
The four FLs and successive B-LBLs express clonally related somatically mutated 195 
IG gamma heavy chains. 196 
IGHV gene analysis showed that in all patients the FL and B-LBL were of the same 197 
clonal origin, harboring identical IGHV rearrangements (Table 3). In TF3b, all four 198 
FACS-sorted fractions, including the small CD19+CD10–CD20hi cells, harbored an 199 
identical IGHV rearrangement, suggesting that this population is either a CD10– subclone 200 
of the FL or represents a stage intermediate between the FL and B-LBL. In accordance 201 
with their GC phenotype, all four FLs harbored somatically mutated IGHV. Intriguingly, 202 
all four lymphomas expressed IgG, as determined by RT-PCR, instead of the commonly 203 
found IgM in FL4 (Table 3). Due to poor DNA quality, the IGHV of the TF3a FL could 204 
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only be investigated from framework 2 (FR2). We were unable to determine the IGHV of 205 
the TF4b DLBCL due to lack of material. 206 
All four FL/B-LBL pairs harbored high numbers of shared somatic IGHV mutations 207 
(Figure 2), further underscoring their clonal relationship. Comparison of individual 208 
molecular IGHV clones of TF1 and TF3 showed intraclonal IGHV sequence variation 209 
(ICV) of the FLs but not of the B-LBLs. Particularly the CD20hi FL cell fractions of TF3b 210 
showed high ICV, whereas ICV was not detected in the CD20lo B-LBL cell fractions 211 
(Figure 2).  212 
 213 
Some B-LBLs show ongoing light chain rearrangement and express surrogate light 214 
chains. 215 
The FL TF1a was found to express an IGLV2-18/IGLJ2/3a rearrangement (Table 3). 216 
Interestingly, after transformation a different monoclonal immunoglobulin lambda 217 
variable region (IGLV) rearrangement was amplified out of the TF1b B-LBL, i.e. IGLV3-218 
21/IGLJ3b. Amplification of IGLV of DNA followed by genescan analysis revealed that 219 
in both the FL and the B-LBL of TF1 two IGLV rearrangements were present (data not 220 
shown). One of these IGLV rearrangements was of the same length before and after 221 
transformation. In accordance with the IGLV sequence analysis, the second IGLV 222 
rearrangement in the B-LBL of TF1b was of a different length than that of the FL of 223 
TF1a. The IGLV3-21 gene segment, identified in the B-LBL, is located more upstream in 224 
the IGLV locus than the IGLV2-18 gene segment of the FL. Most likely, the IGLV3-21 225 
rearrangement of the TF1b B-LBL has emerged by secondary rearrangement of the IGLV. 226 
Similarly, the IGLV1-36/IGLJ3b rearrangement detected in FL TF2a was not found in B-227 
LBL TF2b. In TF2b an oligoclonal rearrangement pattern was seen by genescan analysis 228 
(data not shown). In all FACS-sorted cell populations of TF3b, an identical IGLV4-229 
69/IGLJ2/3a rearrangement was observed. In accordance, a monoclonal IGLV region of 230 
identical length was observed by genescan analyses (data not shown).  231 
The expression of the IG light chain was also assessed by IHC on cryostat sections. The 232 
tumor cells of both the FL and B-LBL of TF1 expressed Igλ, but no Igκ (Table 2), 233 
confirming the RT-PCR analyses. In the B-LBL TF2b, Igλ was exclusively detected.  234 
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IGLV expression of FL TF2a and all TF3 and TF4 samples could not be investigated by 235 
IHC due to lack of frozen tissue. 236 
It has been described that B-LBLs express the surrogate light chain (psi L), which is 237 
composed of two proteins, VpreB and λ5.27 RT-PCR analyses revealed that both the B-238 
LBL of TF1b and TF2b indeed expressed VpreB and lambda5, whereas the preceding FL 239 
of TF1a and TF2a did not (Figure 3). In TF3a and TF3b, VpreB and λ5 expression were 240 
not detected. Due to lack of material, VpreB and λ5 expression was not assessed in TF4. 241 
 242 
All four B-LBLs acquired a MYC gene translocation. 243 
In accordance with the immunohistochemical data, the FLs of TF1a, TF3a and TF4a 244 
harbored translocations of the BCL2 gene as detected by segregation fluorescence in situ 245 
hybridization (FISH) and these translocations were also detected after histological 246 
transformation. Unfortunately, the BCL2 FISH on TF2a was not interpretable, however, 247 
in the TF2c B-LBL a BCL2 translocation was detected (Table 4). In all four patients, 248 
MYC gene translocations were identified after histological transformation. In addition, a 249 
3q27 break, involving BCL6, was found in the FL of TF1a, whereas after progression no 250 
split signals were detected. In contrast, the B-LBL of TF2c showed a 3q27 break only 251 
after transformation. In TF3 and TF4, a 3q27 breakage was not detected in any of the 252 
biopsies. Both in TF3 and TF4, BCL6 protein expression decreased upon transformation, 253 
as detected by IHC (Figure 1). 254 
 255 
Genome wide analyses of TF3 before and after transformation. 256 
To further uncover the genomic aberrations that accompanied progression of the FL of 257 
TF3, the sorted cell populations were analyzed by comparative genomic hybridization 258 
(CGH). The number of genomic aberrations in the FL of TF3b was similar to two control 259 
FLs. In total, the FL and B-LBL fractions of TF3b shared 26 genomic aberrations (Figure 260 
4A), underscoring their clonal relationship. The shared aberrations comprised three 261 
amplifications, three deletions and copy-neutral loss of heterozygosity (CN-LOH) in 20 262 
regions, including deletion of 22q11 and CN-LOH of 6q21 and 7q33, which are all 263 
commonly observed in FLs28 (Table 5). Interestingly, these 26 shared aberrations also 264 
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contained regions previously described to be associated with transformation of FL into 265 
high-grade lymphomas other than B-LBL, such as deletion of 1p36.28 It was noted by 266 
CGH that MYC was amplified in the FL prior to translocation (Figure 4A). The B-LBL 267 
harbored only a limited set of aberrations in addition to the aberrations already present in 268 
the FL, i.e. CN-LOH of 9p, amplification of 14q32 and deletion of 17q12. The affected 269 
region of 9p included CN-LOH of JAK2 and PAX5. Importantly, a small region of 9p21 270 
was deleted, which contains the tumor suppressor genes CDKN2A/B (encoding p15 and 271 
p16) and MTAP (Figure 4B). Genes amplified at 14q32 include the proto-oncogenes 272 
TCL1, BCL11 and AKT1 (PKB). The tumor suppressor gene NF-1 is among the genes 273 
deleted on chromosome 17. In Supplementary Table S2, the affected genes in 9p, 14q32 274 
and 17q12 are listed. In the CD10– fraction, an amplification of chromosome 12 was 275 
gained as compared to the FL fraction. It did however not share any of the aberrations 276 
found in the transformed B-LBL, suggesting that this fraction is a subclone of the FL 277 
rather than a tumor population at an intermediate stage between FL and B-LBL.  278 
 Whole-exome sequencing revealed heterozygous missense mutations in CCND3, 279 
DYSF, ISOC2 and ZFHX4 present in the B-LBL, which were absent in the FL. Two 280 
missense mutations (in SMARCA2 and SNAPC3) heterozygously present in the FL, were 281 
hemizygous in the B-LBL due to LOH of chromosome 9p. In addition, one nonsense 282 
mutation in TNFRSF14 and additional mutations in the 5’UTR of BCL2 and MYC were 283 
found in the B-LBL (Table 6 and Supl. Figure 2). The mutations in CCND3, ISOC2, 284 
MYC and ZFHX4 were found in 7%, 9%, 3% and 6% of the sequence reads and thus 285 
were subclonal variants in the FL. Next to this analysis, we checked a set of genes 286 
previously described to be mutated in FL and B-ALL (see Materials and Methods). This 287 
unveiled missense mutations in FMN2, NEB and SYNE1 as well as a nonsense mutation 288 
in KMT2D, shared by the FL and B-LBL. In addition, 1 synonymous, 2 3’UTR and 14 289 
intronic mutations were identified (Supplementary Table 2). Eleven mutations in ten 290 
genes were validated by Sanger sequencing in TF3b (Supplementary Figure S2). These 291 
mutations were also examined in TF1a, TF2a and TF2c but were however not detected 292 
(data not shown). Moreover, no mutations in the commonly mutated gene EZH2 were 293 
detected in TF1a and TF3b.The loss of CDKN2A/B as detected by CGH was confirmed 294 
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by comparing the numbers of sequence reads (data not shown). .295 
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Discussion 296 
 297 
Transformation of FL into a B-LBL occurs rarely and has been documented for a limited 298 
number of cases.7-15 Here, we describe four B-LBLs that evolved out of FLs and show 299 
that, in spite of retained expression of mutated IGHV genes, the B-LBLs had acquired 300 
several key features of precursor B cells. The follicular architecture as well as CD20 301 
expression were lost, the expression of TdT, VpreB and Lambda5 was induced and 302 
evidence was obtained for reinitiated IGLV gene rearrangement since the expressed IGLV 303 
genes in the B-LBL of TF1b and TF2b were different from those of the FL of TF1a and 304 
TF2a respectively, while the IGHV genes were unaltered.  305 
A t(14;18)(q32;q21) is a rare event in primary B-LBL/B-ALL. Stamatoullas et al. 306 
reported that of 142 adult B-ALLs, only five had a translocation involving the BCL2 307 
gene.29 The Mitelman database contains 12 de novo B-LBLs that harbor both a BCL2 and 308 
a MYC translocation.30 In the studies assembled in the Mitelman database no IGHV 309 
sequence analyses were performed and thus it is not excluded that the t(14;18)+ B-LBLs 310 
include cases that originate from FL.  311 
Here, in all four lymphomas a MYC translocation was gained upon histological 312 
transformation. Secondary MYC translocations have been reported by others in 18 out of 313 
19 FLs transforming into B-LBLs7-15, suggesting that MYC overexpression is mandatory 314 
for transformation into a B-LBL. However, this event by itself is unlikely to impose an 315 
immature B-cell program given the fact that 10% of FLs transforming into a DLBCL also 316 
carry MYC rearrangements.31 Remarkably, in the FL of TF3, MYC was amplified prior to 317 
translocation as determined by CGH. It has been reported in mice that MYC translocation 318 
is promoted by AID activity.32 In this respect, the observations that the FLs of TF2 and 319 
TF3 display intraclonal IGHV sequence variation and that all four FLs express IgG, 320 
whereas the majority of FLs express IgM2, are noteworthy and likely to be AID mediated. 321 
However, by RT-PCR we detected no AID expression in TF1, TF2 or in TF3 (data not 322 
shown). Interestingly, IgG expression was also noticed in two separately reported FLs 323 
that transformed into B-LBLs.13, 14 324 
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In TF2, progression to B-LBL was accompanied by a break at 3q27. Similarly, 325 
BCL6 translocations have also been documented in other de novo t(14;18)+ B-LBLs.29 326 
BCL6 region translocations are known to occur in 6-10% of (grade 3) FLs33, ~30% of 327 
DLBCL33 and ~10% of FL transforming into DLBCL.34 TF2b is a so-called “triple-hit 328 
lymphoma” carrying rearrangements of the BCL2, BCL6 and MYC genes. This 329 
combination of genomic rearrangements has been reported before in sporadic cases of FL 330 
undergoing transformation to DLBCLs as well as in de novo DLBCLs.6, 35, 36 Both the 331 
t(14;18)(q32;q21) and the t(8,14)(q22;q32) disrupt the IG coding region.37, 38 Yet, the 332 
finding that in TF2b IGHV mRNA is still expressed, is not necessarily contradictory since 333 
BCL6 locus rearrangements may engage the IGL chain or non-IG loci, while MYC may 334 
be juxtaposed to downstream IG switch regions thus leaving the IG coding region 335 
intact.39 Alternatively, BCL2 and MYC rearrangement may occur at the same IGH 336 
allele.40 The phenomenon that in TF1 the break at the 3q27 locus was no longer detected 337 
after progression into the B-LBL of TF1b has been reported in FLs transformed to 338 
DLBCL.41 339 
High resolution CGH-array on sorted FL and B-LBL cells from TF3b revealed 340 
that the B-LBL had gained only a limited number of genetic aberrations, i.e. CN-LOH of 341 
9p, deletion of 17q12, amplification of the oncogenes TCL1, BCL11B and AKT, all on 342 
chromosome 14 and amplification of 14q32 which includes the gene encoding the 343 
transcription factor Yin Yang 1 (YY1). YY1 is expressed in early B cells and GC B cells, 344 
where it regulates IGHV -rearrangement and class switch recombination, respectively.42 345 
YY1 has also been shown to activate the MYC promotor.43 The deleted 9p region contains 346 
CDKN2A/B and MTAP and was previously described to be associated with 347 
transformation of FL into DLBCL.5 Loss of CDKN2A/B also occurs in approximately 348 
40% of adult B-ALLs and is associated with poor survival.44 Deletion of the cell cycle 349 
regulators CDKN2A/B may be required for transformation since it renders the cells 350 
resistant to MYC-induced apoptosis.5 It is, however, unlikely that CDKN2A/B loss is 351 
instrumental in the induction of a precursor B-cell phenotype.  352 
PAX5, a master regulator of B-cell lineage commitment and differentiation45 is among the 353 
genes on 9p that show loss of heterozygosity after transformation (listed in 354 
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Supplementary Table 2). Interestingly, mutations in PAX5 were found in approximately 355 
30% of de novo B-LBL, suggesting that loss of expression of this transcription factor 356 
results in a developmental blockade and drives B-LBL development.45 Moreover, it was 357 
shown that PAX5-/- mice have a differentiation arrest at the pro-B-cell stage45, whereas 358 
targeted deletion of PAX5 in mature B cells resulted in loss of the B-cell phenotype and 359 
lymphoblast formation.46 However, we did not detect mutations in the coding region of 360 
PAX5 in TF1, TF2 and TF3 (data not shown) and PAX5 protein expression was 361 
measurable by IHC in all four B-LBLs (Table 2). Still, decreased PAX5 transcription and 362 
protein expression due to the 9p deletion cannot be excluded. Neither did we detect 363 
mutations in IKZF1 in TF3 (data not shown), another master regulator of B-cell 364 
commitment and differentiation, which is frequently deleted in de novo B-LBL.45 365 
 Whole-exome sequencing revealed missense mutations in FMN2, NEB and 366 
SYNE1 as well as a nonsense mutation in KMT2D, shared by the FL (TF3a) and B-LBL 367 
(TF3b) (Supplementary Table 1). These genes were previously described to be mutated in 368 
FL.5, 22-26 KMT2D has a role in epigenetic programming and is considered as a driver 369 
gene of FL.22 As compared to the preceding FL (TF3a), seven missense mutations and 370 
one nonsense mutation were gained in the B-LBL stage. One of the missense mutations in 371 
CCND3 (T283A) is located in exon 5, a region recurrently mutated in DLBCL and BL. In 372 
38% of sporadic BL cases a mutation in CCND3 is present.47 The T283A mutation was 373 
shown to increase protein stability of CCND3 conferring a proliferative advantage.47 In 374 
the FL stage, a deletion of chr. 1p36 was detected, including deletion of TNFRSF14. In 375 
FL, -1p36 is found in frequencies between 20 – 40% and has been correlated with dismal 376 
prognosis.28, 48 Interestingly, in addition to -1p36, in the TF3b B-LBL a nonsense 377 
mutation in TNFRSF14 was found, suggestive for a tumor suppressor role in the 378 
progression of FL. However, there are conflicting reports as to whether the combination 379 
of -1p36 with TNFRSF14 mutation is associated with good or bad overall survival.49, 50 380 
Interestingly, the mutation in SMARCA2 (BRM), which is part of the SWI/SNF ATP-381 
dependent chromatin remodeling complex, was hemizygously found in the B-LBL stage 382 
due to LOH on chromosome 9p.51 Mutations in SMARCA2 and SMARCA4 were 383 
described in marginal zone B-cell lymphoma51, BL and DLBCL.47 SMARCA2 is a 384 
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known interaction partner of C/EBPα, which forms heterodimers with C/EPBβ.52 It has 385 
been shown that C/EPBα and C/EBPβ are involved in B-cell reprogramming to 386 
macrophage-like cells or stem cell-like cells. However, it is unclear whether SMARCA2 387 
interacts with the heterodimer of C/EPBα and β and whether this interaction is necessary 388 
for de role in B-cell reprogramming.53 In addition, SWI/SNF components, including 389 
SMARCA2, are necessary for the accessibility of the CD79A promotor for the 390 
transcription factors PAX5 and EBF1.54 Via these mechanisms the identified mutation in 391 
SMARCA2 may contribute to the lymphoma de-differentiation. Some of the mutations 392 
that were specifically and uniformly detected in the B-LBL (in CCND3, ISOC2, MYC and 393 
ZFHX4) were detectable in 3-9% of the sequence reads in the preceding FL timepoint. 394 
This observation indicates that minor precursor clones containing these mutations were 395 
present in the FL. One subclone of the FL with all these mutations eventually grew out as 396 
the B-LBL. 397 
In a recently published study by Geyer et al. seven FLs, which transformed into 398 
B-LBLs, were analyzed. Similar to our study, all transformation cases were characterized 399 
by loss of follicular architecture, gain of TdT expression and the presence of a MYC gene 400 
rearrangement. The lymphoblastic lymphoma of one case was analyzed by whole-exome 401 
sequencing also identifying mutations in TNFRSF14 and CCND3. Unfortunately, it is 402 
unknown whether these mutations had been present in the FL, as the preceding FL was 403 
not analyzed.12  404 
 Some of the genomic mutations acquired in the B-LBL are also implicated in the 405 
transformation from FL to DLBCL, such as deletion of CDKN2A/B and MYC 406 
translocation. MYC translocation is also essential in BL development and the acquired 407 
CCND3 mutation (T283A) is frequently mutated in this aggressive entity. Although we 408 
also determined several acquired mutations, which were not described in either DLBCL 409 
or BL and intriguingly all FLs transforming to B-LBL expressed IgG, we cannot explain 410 
this peculiar transformation.  411 
 It was previously hypothesized that clonally related FLs and B-LBLs do not 412 
develop sequentially but might evolve in parallel from precursor cells harboring the 413 
t(14;18).8, 37 A t(14;18)+ sIG- and TdT+ B-cell might thus evolve into a TdT-CD20+ FL or 414 
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expand as a precursor B cell by acquisition of an additional MYC translocation. However, 415 
more recent work has shown that after the acquisition of the t(14;18) in bone marrow 416 
precursor B cells, these t(14;18) positive B cells further mature to memory B cells and 417 
acquire somatic hypermutations in successive rounds of re-entry in germinal centres.55 418 
Thus the B-LBL might originate from mature post-germinal center B cells functioning as 419 
FL precursor cells that undergo a further round of re-entry in a germinal center, thereby 420 
acquiring an AID induced MYC breakpoint. For still unknown reasons they also show 421 
partial regression to a phenotype of precursor B cells. Our study, however, demonstrates 422 
that the B-LBLs evolve from FL subclones that already accumulated the vast majority 423 
(for TF2 all) of the somatic IGHV mutations and for TF3 also the majority of the genomic 424 
aberrations. Whatever the exact mechanism may be, these data clearly show that the FL 425 
and B-LBL pairs did not arise in parallel from t(14;18)+ IG unmutated precursor cells. 426 
427 
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Table 1. Four patients with a FL that has transformed into a B-LBL 
 
Patient Sex Age Diagnosis Years from   
FL diagnosis 
Location 
      
TF1a 
TF1b 
F 57 FL 
B-LBL 
0 
2 
lymph node 
epicardium 
      
TF2a 
TF2b 
TF2c 
F 51 FL 
B-LBL 
B-LBL 
0 
1 
2 
lymph node 
mouth 
mouth 
      
TF3a 
TF3b 
F 24 FL 
FL 
B-LBL 
0 
2 
2 
lymph node 
lymph node 
lymph node 
      
TF4a 
TF4b 
TF4c 
M 54 FL 
DLBCL 
B-LBL 
0 
1 
1 
lymph node 
abdominal wall  
retroperitoneum 
      
 
B-LBL, precursor B-lymphoblastic lymphoma; FL, follicular lymphoma ; F, female; M, 
male. 
In TF1b, TF2b and TF4b the pre-existing FL was no longer present, whereas in TF3b 
both the FL and B-LBL were detected. The biopsies of TF2b and TF2c were both taken 
from the mucosa of the jaw. 
Patients TF1, TF2, TF3 and TF4 all died within two years after FL diagnosis. 
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Table 2. Immunophenotypes of four lymphomas before and after progression. 
 
Protein expression of CD20, CD21-L, CD10, BCL6, BCL2, TdT, Pax5, CD79a, CD19 
and Ig, as determined by immunohistochemistry (IHC) on FFPE and frozen sections. B-
LBL, precursor B-cell lymphoblastic lymphoma; FL, follicular lymphoma; LN, lymph 
node; FDC, follicular dendritic cells (as determined by CD21-L staining); nd, not 
determined due to lack of appropriate patient material.  
Patient Diagnosis CD20 FDC CD10 BCL6 BCL2 TdT Pax5 CD79a CD19 Igλ Igκ 
             
TF1a 
TF1b 
FL 
B-LBL 
+ 
- 
+ 
nd 
+ 
+ 
+ 
- 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
             
TF2a 
TF2b 
TF2c 
FL 
B-LBL 
B-LBL 
+ 
- 
- 
+ 
nd 
nd 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
nd 
+ 
+ 
nd 
+ 
+ 
nd 
- 
- 
             
TF3a 
TF3b 
FL 
FL 
B-LBL 
+ 
+ 
- 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
+ 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
nd 
+ 
+ 
nd 
nd 
nd 
nd 
nd 
nd 
             
TF4a 
TF4b 
TF4c 
FL 
DLBCL 
B-LBL 
+ 
- 
- 
nd 
- 
- 
+ 
+ 
+ 
+ 
- 
- 
+ 
+ 
+ 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
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Table 3. IGHV and IGLV rearrangements of the four FLs and in their ensuing B-
LBL.  
 
Patient Diagnosis Subclass IGHV-rearrangment Mut# 
(shared with FL) 
IGLV-rearrangement 
      
TF1a 
TF1b 
FL 
B-LBL 
IgG 
IgG 
IGHV4-61/na/IGHJ5a 
IGHV4-61/na/IGHJ5a 
22  
27 (19) 
IGLV2-18/IGLJ2/3a 
IGLV3-21/IGLJ3b 
      
TF2a 
TF2b 
FL 
B-LBL 
IgG 
IgG 
IGHV3-20/na/IGHJ6b 
IGHV3-20/na/IGHJ6b 
23  
23 (23) 
IGLV1-36/IGLJ3b 
polyclonal 
      
TF3a 
TF3b† 
FL 
FL (CD10hi) 
FL (CD10low) 
B-LBL (S) 
B-LBL (L) 
Nd 
IgG 
IgG 
IgG 
IgG 
IGHV1-69/IGHD1-26/IGHJ6c 
IGHV1-69/IGHD1-26/IGHJ6c 
IGHV1-69/IGHD1-26/IGHJ6c 
IGHV1-69/IGHD1-26/IGHJ6c 
IGHV1-69/IGHD1-26/IGHJ6c 
10* 
17 
15  
15 (14) 
15 (14) 
nd 
IGLV4-69/IGLJ2/3a 
IGLV4-69/IGLJ2/3a 
IGLV4-69/IGLJ2/3a 
IGLV4-69/IGLJ2/3a 
      
TF4a 
TF4b 
TF4c 
FL 
DLBCL 
B-LBL 
IgG 
nd 
IgG 
IGHV3-73/IGHD1-7/IGHJ5*02 
nd 
IGHV3-73/na/ IGHJ5*02 
21 
nd 
25 (18) 
nd 
nd 
nd 
      
 
* IGHV SHM was determined starting from framework (FR) 1 in all instances, except for 
TF3a, in which SHM were determined starting from FR2 and TF4, in which SHM could 
not be determined in the first part of FR1.  
† Lymph node suspensions of TF3b were sorted in 4 fractions (See Figure S1 and text). 
na, not applicable. 
nd, not determined 
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Table 4. Chromosomal translocations detected by FISH analysis.  
 
Patient BCL2 MYC BCL6 
    
TF1a 
TF1b 
+ 
+ 
- 
+ 
+ 
- 
    
TF2a 
TF2c 
ni 
+ 
- 
+ 
- 
+ 
    
TF3a 
TF3b 
+ 
+ 
- 
+ 
- 
- 
    
TF4a 
TF4b 
TF4c 
+ 
+ 
+ 
- 
- 
+ 
- 
nd 
- 
    
 
ni: not interpretable; nd: not determined 
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Table 5. Numerical genomic aberrations in TF3. 
 
Region FL B-LBL Remarks 
    
1p36 del. del. Associated with transformation of FL 
2p16 CN-LOH CN-LOH Ampl. associated with transformation of FL 
5p12 CN-LOH CN-LOH Ampl. associated with transformation of FL 
6q21 CN-LOH CN-LOH Del. in 17% of FL28 
6q22 CN-LOH CN-LOH Ampl. associated with transformation of FL 
7q33 CN-LOH CN-LOH LOH in 11% of FL28 
8q ampl. ampl. Includes ampl. of MYC 
9p wt CN-LOH Includes del. of CDKN2 
14q32 wt ampl. Includes ampl. of TCL1 and BCL11 
17q12 wt del. Includes del. of NF-1 
22q11 del. del. Del. in 10% of FL28 
    
 
del.: deletion; CN-LOH: copy neutral loss of heterozygosity; ampl.: amplification; wt: 
wildtype
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Table 6. Exome mutations gained in the B-LBL of TF3b. 
 
Gene Chromosome Position Mutationtype RefSeq Mutation FL B-LBL 
        
BCL2 18 60986079 5’UTR NM_00633 5UTR-180 C/T wt het 
CCND3 6 41903710 missense NM_001760 K268R (A803G) wt het 
  41903754 missense  T283A (A847G) wt het 
DYSF 2 71908237 missense NM_01130987 P2057Q (C6170A) wt het 
ISOC2 19 55967760 missense NM_01136201 G94A (A32T) wt het 
MYC 8 128748820 5’UTR NM_002467 5UTR+19 T/C wt het 
SMARCA2 9 2081868 missense NM_003070 N741H (A2221C) het hem 
SNAPC3 9 15451376 missense NM_001039697 T264S (A791C) het hem 
TNFRSF14 1 2488138 nonsense NM_003820 W12* (G35A) wt hom 
ZFHX4 8 77763412 missense NM_024721 H1419Y (C4255T) wt het 
        
 
wt: wildtype; het: heterozygous; hom: homozygous; hem: hemizygous
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Figure legends 
 
Figure 1: Histology and immunophenotype of TF3 before and after transformation.  
TF3a showed a follicular growth pattern and expressed CD20, BCL6 and BCL2. After 
transformation part of the tumor cells of TF3b retained a follicular growth pattern (as 
indicated by an arrowhead), which was alternated by sheets of lymphoblastic cells (as 
indicated by an arrow). The FL cells still expressed CD20, BCL6 and BCL2, whereas the 
B-LBL cells lacked expression of CD20 and BCL6 but expressed TdT.  
 
Figure 2: IGHV configurations of FL and B-LBL.  
Schematic representation of IGHV consensus sequences of TF1-4 before and after 
progression. Vertical bars correspond to shared mutations between the FL and B-LBL.   
V corresponds to two shared mutations in the same codon. Non-shared replacement and 
silent mutations are indicated by closed and open lollipop symbols, respectively. Codon 
numbering is according to V-Quest 
(http://www.imgt.org/IMGT_vquest/vquest?livret=0&Option=humanIg).18 Black boxes 
indicate parts of the IGHV gene that were not sequenced. ICV denotes the degree of 
intraclonal variation. 
 
Figure 3: VpreB and lambda5 are expressed in the B-LBL but not in the FL.  
RT-PCR analysis of VpreB and Lambda5 expression before and after progression.            
B2M: β-2-microglobulin. TF3 was sorted in four fractions (see figure S1 and text). The – 
indicates a negative H2O control and the pre-B-cell line Nalm-6 was used as a positive 
control (+). 
 
Figure 4: Genomic aberrations of TF3b FL and B-LBL as determined by 
comparative genomic hybridization. 
(A) Overview of genomic aberrations of the four sorted cell populations of TF3b and two 
control FLs, as determined by comparative genomic hybridization. Red indicates 
homozygous deletion. Orange indicates heterozygous deletion. Green indicates copy-
26 
 
neutral loss of heterozygosity (CN-LOH). Blue indicates 2-fold amplification. Purple 
indicates >3-fold amplification. (B) Allele frequency of chromosome 9p in the B-LBL of 
TF3b. The green area indicates CN-LOH. Red indicates deletion. 
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